Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Cancer Res. 2009 Apr 7;69(8):3689–3694. doi: 10.1158/0008-5472.CAN-09-0024

Figure 3.

Figure 3

Modulation of PI3K signaling reduces cell proliferation in vitro and in vivo. A, growth curve of tumor cells upon treatment with LY294002 and PD98059. The graph represents one of at least four independent experiments, on three different cell lines. B, Western blot analysis of ERK1/2 activation upon PI3K or MEK pharmacological inhibition. C, PI3K inhibition allows activated Kras to induce senescence in tumor-derived cell lines. The panels show a representative experiment (of three independent experiments, on different cell lines) using 10μM LY and 50μM PD for six days. D, in vivo administration of 25mg/kg LY294002 prolongs the survival of DM mice (n=9 LY-treated and 15 controls).